Medicines Company beats Mylan in Angiomax patent case
This article was originally published in Scrip
Executive Summary
The Medicines Company (MDCO) prevailed in US District Court for the Northern District of Illinois where Judge Amy St Eve determined that MDCO's patent was valid and infringed by Mylan's planned generic version of the anticoagulant Angiomax (bivalirudin).